



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/088,775	09/16/2002	Norman Latov	61546-A-PCT-US/JPW/FHB 2322		
7590 10/19/2004			EXAMINER		
John P White			GRUN, JAMES LESLIE		
Cooper & Dunham 1185 Avenue of the Americas			ART UNIT PAPER NUMP		
New York, NY 10036			1641		
			DATE MAILED: 10/19/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

<del>-}</del>		Application	No.	Applicant(s)				
Office Action Summary								
		10/088,775						
		Examiner		Art Unit				
		James L Gru		1641				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
THE   - Exter after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPI MAILING DATE OF THIS COMMUNICATION nsions of time may be available under the provisions of 37 CFR 1 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a re period for reply is specified above, the maximum statutory perior re to reply within the set or extended period for reply will, by statu- reply received by the Office later than three months after the mailing ad patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, ply within the statutor d will apply and will e tte, cause the applica	however, may a reply be tim ry minimum of thirty (30) days xpire SIX (6) MONTHS from tion to become ABANDONEI	riely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status								
1)[🛛	1) Responsive to communication(s) filed on 13 July 2004.							
2a)⊠	This action is <b>FINAL</b> . 2b) This action is non-final.							
3)[	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposit	on of Claims							
- 4)⊠ 5)□ 6)⊠ 7)□	4) Claim(s) 1-4,7-12 and 14-35 is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.  5) Claim(s) is/are allowed.  6) Claim(s) 1-4,7-12 and 14-35 is/are rejected.  7) Claim(s) is/are objected to.  8) Claim(s) are subject to restriction and/or election requirement.							
Applicat	ion Papers							
9) The specification is objected to by the Examiner.								
10)	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11)	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority (	ınder 35 U.S.C. § 119							
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of: <ol> <li>Certified copies of the priority documents have been received.</li> <li>Certified copies of the priority documents have been received in Application No.</li> <li>Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> </ol> </li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>								
Attachmer	at(s)							
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)								
3) Infor	ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/0 er No(s)/Mail Date	,0,	Paper No(s)/Mail Da )  Notice of Informal P ) Other:	ate Patent Application (PTO-152)				

Application/Control Number: 10/088,775

Art Unit: 1641

To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Technology Center 1600, Group 1640, Art Unit 1641.

The amendment filed 13 July 2004 is acknowledged and has been entered. Claims 5, 6, and 13 have been cancelled. Claims 1-4, 7-12, and 14-35 remain in the case.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The specification is objected to under 35 U.S.C. § 112, first paragraph, as failing to provide an adequate written description of the invention, and failing to adequately teach how to make and/or use the invention, i.e. failing to provide an enabling disclosure.

Claims 1-4, 7-12, 14, 15, and 17-35 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention, and which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Applicant teaches a single total ganglioside preparation, obtained commercially, which is indicated parenthetically as being a Ca<sup>++</sup> salt. Although one of skill in the art might realize from reading the disclosure that calcium salts of other particular gangliosides are useable in the invention, such possibility of use

Application/Control Number: 10/088,775

Art Unit: 1641

does not provide explicit or implicit indication to one of skill in the art that the uses of calcium salts for all gangliosides were originally contemplated as part of applicant's invention and such possibility of use does not satisfy the written description requirements of 35 U.S.C. § 112, first paragraph. Note that a description which renders obvious a claimed invention is not sufficient to satisfy the written description requirement. Applicant is requested to direct the Examiner's attention to specific passages where support for these newly recited limitations can be found in the specification as filed, for other than the bovine brain extract obtained from Sigma Chemical Co., or is required to delete the new matter.

Claims 1-4, 7-12, and 14-35 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Uhlig et al. (Autoimmunity 5: 87-99, 1989) in view of Dwyer et al., Uemura et al. (Biochem. J. 219:865, 1984), Ravindranaths et al. (J. Biol. Chem. 263:2079, 1988), Pestronk (U.S. Pat. No. 5,443,952), applicant's admissions regarding the prior art, and Beltz et al. (U.S. Pat. No. 4,753,873) for reasons of record. In addition to the reasons of record set forth in the previous Office action, it would have been obvious to one of ordinary skill in the art to have used any available preparation of the desired gangliosides such as that used in Uhlig et al., purchased from Sigma Chemical Co.

Applicant's arguments filed 13 July 2004 have been fully considered but they are not deemed to be persuasive. Applicant urges that the combination of references does not teach the use of calcium salts of gangliosides as is now claimed. This is not found persuasive for the reasons set forth above. Uhlig et al. appears to have obtained the same mixture of gangliosides

Application/Control Number: 10/088,775

Art Unit: 1641

from the same supplier, therefore taken by the examiner, absent evidence to the contrary, as having the same properties.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A SHORTENED STATUTORY PERIOD FOR REPLY TO THIS FINAL ACTION IS SET TO EXPIRE **THREE MONTHS** FROM THE MAILING DATE OF THIS ACTION. IN THE EVENT A FIRST REPLY IS FILED WITHIN **TWO MONTHS** OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT MAILED UNTIL AFTER THE END OF THE **THREE-MONTH** SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 C.F.R. § 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR REPLY EXPIRE LATER THAN **SIX MONTHS** FROM THE MAILING DATE OF THIS FINAL ACTION.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James L. Grun, Ph.D., whose telephone number is (571) 272-0821. The examiner can normally be reached on weekdays from 9 a.m. to 5 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le, SPE, can be contacted at (571) 272-0823.

The phone numbers for official facsimile transmitted communications to TC 1600, Group 1640, are (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application, or requests to supply missing elements from Office communications, should be directed to the Group receptionist whose telephone number is (571) 272-1600.

James L. Grun, Ph.D. October 14, 2004

CHRISTOPHER L. CHIN PRIMARY EXAMINER GROUP 1800-/64/

10/15/04

Christian L. Chin